Newsletters

Newsletters published on November 10, 2021
Join Dr. Stephens as she explains targeted therapies for CLL/SLL and MCL. She will also describe associated adverse events and how to manage them.

For more information on BTK inhibitors in CLL and MCL, click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.

Newsletters published on September 22, 2021
In this activity, experts review optimal BTKi therapy for patients with CLL or MCL and strategies for preventing and managing adverse events associated with BTKi therapy.

For more information on BTK inhibitors in CLL and MCL, click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.

Newsletters published on July 20, 2021
Join Dr. Shanbhag as he discusses the challenges in providing optimal care to patients with chronic lymphocytic leukemia (CLL) in rural areas, including treatment access, clinical trial enrollment, and lack of health insurance, as well as strategies for overcoming some of these barriers so patients with CLL in rural areas can obtain maximum treatment benefit.

For more information on CLL in Rural America, click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from AbbVie, Genentech, and Pharmacyclics.

Newsletters published on May 9, 2021
The incidence rate of CLL in the US overall is about 5 per 100,000. In this newsletter, Dr. Gary Schwartz describes the epidemiology of CLL in rural America.

For more information on CLL in Rural America, click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from AbbVie, Genentech, and Pharmacyclics.


Results 1 - 4 of 4